Evidence map›Paper›PMID 30115692›Full record

ArticleCancer research2018

Mi-Yeon Jung, Chetan P Offord, Matthew K Ennis, Iris Kemler, Claudia Neuhauser, David Dingli

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Oncolytic virotherapy -Oncotarget · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mi-Yeon JungDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
Chetan P OffordDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
Matthew K EnnisDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
Iris KemlerDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
Claudia NeuhauserCollege of Biological Sciences, University of Minnesota, Twin Cities, Minnesota.ORCID 0001-8932-675X
David DingliDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota. dingli.david@mayo.edu.
Mayo Clinic · USUniversity of Minnesota · US

Funding

Molecular imaging and system dynamics of tumor virotherapyR01CA164241 · NCI · MAYO CLINIC ROCHESTER · PI DINGLI, DAVID J · 2011 to 2015
$2.5M
NCI NIH HHS R01 CA164241
6 · The paper itself

Abstract

The use of replication-competent viruses as oncolytic agents is rapidly expanding, with several oncolytic viruses approved for cancer therapy. As responses to therapy are highly variable, understanding the dynamics of therapy is critical for optimal application of virotherapy in practice. Although mathematical models have been developed to understand the dynamics of tumor virotherapy, a scarcity of

Indexed as

Oncolytic VirotherapyAnimalsAnisotropyCell Line, TumorChlorocebus aethiopsFemaleHumansIodidesKineticsMeasles virusMiceMice, Inbred BALB CMice, NudeNeoplasmsOncolytic VirusesRadioisotopesIodidesRadioisotopesSodium-Iodide SymportersSymporters

Identifiers

PMID30115692
PMCPMC6191353
OpenAlexW2887992554

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.